A randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjogrens syndrome
Phase of Trial: Phase III
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- Acronyms TRACTISS
- 17 Jun 2017 Results (n=66) of substudy presented at the 18th Annual Congress of the European League Against Rheumatism.
- 10 Mar 2017 Primary endpoint (Visual Analogue Scale: achievement of a 30% reduction at 48 weeks from baseline in either oral dryness or fatigue measured using patient-completed visual analogue scales) has not been met, according to results published in the Arthritis and Rheumatology Journal.
- 10 Mar 2017 Results of clinical efficacy and cost-effective analysis of rituximab, published in the Arthritis and Rheumatology Journal.